Abstract: A therapeutic compound of the chlorambucil family conjugated to two or three acyl groups derived from fatty acids. The compound has the following formula.

Abstract: The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non-steroidal anti-infiammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.

Abstract: A therapeutic compound of the chlorambucil family conjugated to two or three acyl groups derived from fatty acids. The compound has the following formula. in which X is chlorambucil, Y is an optional spacer group, AA is an amino acid, B is H or CH2O—R3, and n is a number from 0 to 3. X is linked to Y via the carboxyl group. R1, R2 and R3 are as defined by the present specification.

Abstract: The present invention provides self-adjuvanting vaccines for use in raising antibodies to peptides without the use of oil or alum adjuvants. Further, the present invention provides methods of therapy using these vaccines and has particular application in chemical castration. In one aspect the vaccine comprises in admixture a peptide conjugated to 1-3 fatty acids and a peptide conjugated to a carrier protein. In preferred forms the peptide is conjugated to the fatty acids via a tromethamine or ethanolamine derivative. The preferred protein carrier is Type 4 fimbriae.

Abstract: A methotrexate conjugated to 1-3 acyl groups derived from fatty acids. In particular the invention relates to altering the pharmacokinetic profile and mode of delivery of methotrexate by conjugating it to 1.2 or 3 acyl derivatives of fatty acids.

Abstract: The present invention provides a method for introducing nucleic acids into cells. The method involves exposing the cells to a compound having formula (1), in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or is absent, R.sub.4 is H ir CH.sub.2 O--R.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are the same or different and are either hydrogen, methyl, ethyl, hydroxyl or an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated, with the proviso that at least one of R.sub.1, R.sub.2 and R.sub.3 is an acyl group derived from a fatty acid, or to a compound having the formula (2): w . . . xyNHCH.sub.2 CH.sub.2 OR.sub.5, in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or absent, R.sub.5 is an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated.

Abstract: The present invention provides novel compounds in which peptides, amino acids or derivatives thereof are bound to other molecules, in particular fatty acids, which facilitate the use of such peptides, amino acids or derivatives thereof. The basic structure of the compounds of the present invention are an amino acid, peptide or derivative thereof linked to 1 to 3 fatty acid molecules via a tromethamine derivative. Alternatively, the amino acid, peptide or derivative thereof may be linked to a fatty acid by an ethanolamine derivative.

Abstract: The present invention provides a method for introducing nucleic acids into cells. The method involves exposing the cells to a compound having the formula ##STR1## in which: w is a nucleic acidx is a non-amino acid or non-peptide nucleic acid binding groupy is a spacer having a chain length equivalent to 1-30 carbon-carbon single covalent bonds or is absentR.sub.4 is H or halogen or CH.sub.2 O--R.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are the same or different and are either hydrogen, methyl, ethyl, alkyl, alkenyl, hydroxylated alkyl, hydroxylated alkenyl groups or ether containing alkyl, alkenyl, hydroxylated alkyl or hydroxylated alkenyl groups optionally being an acyl group having a carbon chain length equivalent to 3-24 carbon atoms saturated or unsaturated, with the proviso that at least one of R.sub.1, R.sub.2 or R.sub.3 includes a group having a carbon chain of 3-24 carbon atoms saturated or unsaturated, or to a compound having the formula:w . . . y--y--NH--CH.sub.2 --CH.sub.2 O--R.sub.

Abstract: The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non.about.steroidal anti.about.inflammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.